Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results this Tuesday after market close. Here’s what you need to know.
LeMaitre met analysts’ revenue expectations last quarter, reporting revenues of $66.55 million, up 11.2% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ EPS guidance for next quarter estimates and a beat of analysts’ EPS estimates.
Is LeMaitre a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting LeMaitre’s revenue to grow 11.5% year on year, slowing from the 15% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. LeMaitre has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at LeMaitre’s peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Intuitive Surgical delivered year-on-year revenue growth of 18.5%, beating analysts’ expectations by 2.5%, and Integra LifeSciences reported flat revenue, in line with consensus estimates. Intuitive Surgical traded down 14.1% following the results while Integra LifeSciences was also down 13.4%.
Read our full analysis of Intuitive Surgical’s results here and Integra LifeSciences’s results here.
Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. LeMaitre is down 2.5% during the same time and is heading into earnings with an average analyst price target of $118.75 (compared to the current share price of $101.32).
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.